Company
Every investor coverage indicates participated in a round Abbott raised.
Companies Abbott acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Abbott. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech Paradigm Biopharmaceuticals appoints rheumatology specialist Daniel Furtner as chief medical officer; predecessor Donna Skerrett stays as senior scientific advisor, and the firm's late-stage osteoarthritis trial has finished enrolling 538 participants.
Ten13's post explains why it joined the robotics company's latest raise alongside Blackbird, Neotribe, Startmate and Horizons, covering its autonomous scanning device, dialysis focus, founders, and US rollout plans.
Vively, founded by triathlete Tim Veron after reversing his pre-diabetes, raised $1.6 million seed funding led by Archangel Ventures with Bupa Ventures, and has partnered with Bupa to make continuous glucose monitoring more affordable.
Cardiac device maker EBR Systems has won US regulator clearance for its leadless heart-failure therapy, clearing the way for staged commercial release later in 2025 and broader distribution in 2026.
EBR Systems has won US regulatory approval for its WiSE implant, the first leadless device for a form of cardiac resynchronization therapy, which the CEO frames as the end of a 22-year development phase.
AgFunderNews' monthly roundup of agrifood leadership changes: a new CFO at Little Leaf Farms, co-CEOs at Incredo, Chobani's new CMO, plus appointments, departures and layoffs across sector companies.